Previous 10 | Next 10 |
home / stock / snynf / snynf news
2024-06-06 08:04:56 ET More on Sanofi, Novavax, etc. Novavax: Sanofi Partnership Revitalizes My Magnum Opus Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade) Bird flu death in Me...
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sa...
2024-05-31 06:49:06 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Regeneron Pharmaceuticals, Inc. (REGN) Q1...
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th year, the program demonstrates the ongoing commitment of S...
2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...
Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc . (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the com...
2024-05-30 07:04:27 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna down ~9%, likely ending 10-sessio...
2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with stand...
2024-05-22 15:38:02 ET More on Bristol-Myers, Sanofi, etc. Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Brist...
News, Short Squeeze, Breakout and More Instantly...
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee Paris, June 21, 2024 . Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President, has been named Executive Vice President, Global Head ...
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim r...
Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. ...